
|Articles|April 1, 2004
HUMAX-CD4 STUDY
Genmab A/S presented data from Phase II HuMax-CD4 studies to treat cutaneous T-cell lymphoma (CTCL) at the 65th annual meeting of the Society for Investigative Dermatology in April. At the time the abstract was completed, 36 patients enrolled in the two ongoing HuMax-CD4 clinical trials were evaluated using the Composite Assessment of Index Lesion Disease Activity (CA) score.
Advertisement
Newsletter
Like what you’re reading? Subscribe to Dermatology Times for weekly updates on therapies, innovations, and real-world practice tips.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Dermatology Times
1
Improving Outcomes in Acne, Hidradenitis Suppurativa, and Vitiligo Through Treatment Advancements
2
Psychodermatology’s Role in Strengthening Therapeutic Connections
3
Day 4 Recap: Elevate-Derm Fall Conference
4
Treatment Plan Expectations and Previewing the 2026 Pipeline
5



















